Drug Profile
Research programme: brain injury therapeutics - Chiesi
Latest Information Update: 08 Feb 2023
Price :
$50
*
At a glance
- Originator Chiesi
- Class
- Mechanism of Action Caspase inhibitors; Melatonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain injuries
Most Recent Events
- 08 Feb 2023 Preclinical trials in Brain injuries in Italy (unspecified route) prior to February 2023 (Chiesi pipeline, February 2023)
- 08 Feb 2023 Preclinical trials in Brain injuries in USA (unspecified route) prior to February 2023 (Chiesi pipeline, February 2023)
- 06 Aug 2021 Brain injury therapeutics is still in early research phase for Brain injuries in Italy (Chiesi Farmaceutici pipeline, August 2021)